vs
Aclarion, Inc.（ACON）与GRAIL, Inc.（GRAL）财务数据对比。点击上方公司名可切换其他公司
GRAIL, Inc.的季度营收约是Aclarion, Inc.的2359.4倍（$43.6M vs $18.5K）。GRAIL, Inc.净利率更高（-227.5% vs -10223.7%，领先9996.3%）。Aclarion, Inc.同比增速更快（80.6% vs 14.0%）。过去两年Aclarion, Inc.的营收复合增速更高（35.2% vs 27.7%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
GRAIL是2015年成立的美国生物技术企业，总部位于加利福尼亚州门洛帕克，核心业务是研发面向无症状人群的癌症早期筛查检测产品。该公司最初是基因测序企业Illumina旗下的初创子公司，2021年被Illumina全资收购。
ACON vs GRAL — 直观对比
营收规模更大
GRAL
是对方的2359.4倍
$18.5K
营收增速更快
ACON
高出66.6%
14.0%
净利率更高
GRAL
高出9996.3%
-10223.7%
两年增速更快
ACON
近两年复合增速
27.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $43.6M |
| 净利润 | $-1.9M | $-99.2M |
| 毛利率 | 9.7% | — |
| 营业利润率 | -10785.8% | -285.4% |
| 净利率 | -10223.7% | -227.5% |
| 营收同比 | 80.6% | 14.0% |
| 净利润同比 | 5.0% | -2.2% |
| 每股收益（稀释后） | $1.39 | $-2.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONGRAL
| Q4 25 | $18.5K | $43.6M | ||
| Q3 25 | $18.9K | $36.2M | ||
| Q2 25 | $19.3K | $35.5M | ||
| Q1 25 | $19.0K | $31.8M | ||
| Q4 24 | $10.2K | $38.3M | ||
| Q3 24 | $14.4K | $28.7M | ||
| Q2 24 | $11.0K | $32.0M | ||
| Q1 24 | $10.1K | $26.7M |
净利润ACONGRAL
| Q4 25 | $-1.9M | $-99.2M | ||
| Q3 25 | $-1.7M | $-89.0M | ||
| Q2 25 | $-1.6M | $-114.0M | ||
| Q1 25 | $-2.0M | $-106.2M | ||
| Q4 24 | $-2.0M | $-97.1M | ||
| Q3 24 | $-1.4M | $-125.7M | ||
| Q2 24 | $-1.2M | $-1.6B | ||
| Q1 24 | $-2.4M | $-218.9M |
毛利率ACONGRAL
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | — | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | — | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
营业利润率ACONGRAL
| Q4 25 | -10785.8% | -285.4% | ||
| Q3 25 | -9666.2% | -346.2% | ||
| Q2 25 | -8988.6% | -446.9% | ||
| Q1 25 | -7856.0% | -482.5% | ||
| Q4 24 | -17652.7% | -358.0% | ||
| Q3 24 | -8995.3% | -640.5% | ||
| Q2 24 | -10350.6% | -5133.8% | ||
| Q1 24 | -12609.3% | -851.1% |
净利率ACONGRAL
| Q4 25 | -10223.7% | -227.5% | ||
| Q3 25 | -9008.0% | -245.8% | ||
| Q2 25 | -8285.9% | -320.7% | ||
| Q1 25 | -10728.4% | -333.6% | ||
| Q4 24 | -19444.6% | -253.8% | ||
| Q3 24 | -9482.7% | -438.7% | ||
| Q2 24 | -11285.0% | -4958.8% | ||
| Q1 24 | -23720.6% | -819.3% |
每股收益（稀释后）ACONGRAL
| Q4 25 | $1.39 | $-2.37 | ||
| Q3 25 | $-2.93 | $-2.46 | ||
| Q2 25 | $-2.75 | $-3.18 | ||
| Q1 25 | $-9.32 | $-3.10 | ||
| Q4 24 | $-809.36 | $-1.49 | ||
| Q3 24 | $-1321.49 | $-3.94 | ||
| Q2 24 | $-1362.83 | $-51.06 | ||
| Q1 24 | $-3985.22 | $-7.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $249.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.8M | $2.6B |
| 总资产 | $13.7M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONGRAL
| Q4 25 | $12.0M | $249.7M | ||
| Q3 25 | $11.3M | $126.9M | ||
| Q2 25 | $12.8M | $127.4M | ||
| Q1 25 | $14.8M | $133.9M | ||
| Q4 24 | $453.7K | $214.2M | ||
| Q3 24 | $1.3M | $853.6M | ||
| Q2 24 | $1.2M | $958.8M | ||
| Q1 24 | $2.1M | $199.7M |
股东权益ACONGRAL
| Q4 25 | $12.8M | $2.6B | ||
| Q3 25 | $12.5M | $2.2B | ||
| Q2 25 | $14.2M | $2.3B | ||
| Q1 25 | $15.8M | $2.4B | ||
| Q4 24 | $970.1K | $2.5B | ||
| Q3 24 | $2.5M | $2.6B | ||
| Q2 24 | $1.6M | $2.7B | ||
| Q1 24 | $2.5M | — |
总资产ACONGRAL
| Q4 25 | $13.7M | $2.9B | ||
| Q3 25 | $13.2M | $2.6B | ||
| Q2 25 | $14.8M | $2.7B | ||
| Q1 25 | $16.5M | $2.8B | ||
| Q4 24 | $2.1M | $3.0B | ||
| Q3 24 | $3.2M | $3.1B | ||
| Q2 24 | $3.1M | $3.3B | ||
| Q1 24 | $3.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $-63.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-63.9M |
| 自由现金流率自由现金流/营收 | — | -146.5% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-299.9M |
8季度趋势，按日历期对齐
经营现金流ACONGRAL
| Q4 25 | $-1.6M | $-63.8M | ||
| Q3 25 | $-1.2M | $-63.2M | ||
| Q2 25 | $-1.9M | $-77.0M | ||
| Q1 25 | $-2.5M | $-95.0M | ||
| Q4 24 | $-922.9K | — | ||
| Q3 24 | $-1.1M | $-104.6M | ||
| Q2 24 | $-1.1M | $-171.8M | ||
| Q1 24 | $-2.2M | $-207.3M |
自由现金流ACONGRAL
| Q4 25 | — | $-63.9M | ||
| Q3 25 | $-1.2M | $-63.6M | ||
| Q2 25 | — | $-77.3M | ||
| Q1 25 | — | $-95.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-105.6M | ||
| Q2 24 | — | $-173.2M | ||
| Q1 24 | — | $-209.8M |
自由现金流率ACONGRAL
| Q4 25 | — | -146.5% | ||
| Q3 25 | -6164.6% | -175.8% | ||
| Q2 25 | — | -217.6% | ||
| Q1 25 | — | -298.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -368.4% | ||
| Q2 24 | — | -541.7% | ||
| Q1 24 | — | -785.3% |
资本支出强度ACONGRAL
| Q4 25 | — | 0.2% | ||
| Q3 25 | 38.6% | 1.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 9.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
